



Advanced
Accelerator
Applications

A Novartis Company

Reimagining Nuclear Medicine

Transforming patients' lives by leading innovation

Advanced Accelerator Applications (AAA) is an innovative medicines company focused on the development of targeted radioligand therapies and precision imaging radioligands for oncology.

Inspired by his work in advanced physics conducted at the European Organization for Nuclear Research (CERN) the company was founded by an Italian physicist in 2002 and has since developed a legacy as a pioneer in the development and delivery of radiopharmaceutical products. AAA also has an active research and development pipeline of investigational drugs using radiolabeled targeting molecules in multiple cancer types.



Rich Oncology Pipeline
targeting multiple tumor types



Reimagining
nuclear medicine by developing drugs
for targeted radioligand therapy and precision
radioligand imaging



Proud Legacy
of pioneering new advances for patients
since 2002



1100 Associates
across 31 sites in 12 countries



**Global Manufacturing
Capabilities**
19 facilities in 8 countries
and 6 research & development sites






About Nuclear Medicine

Nuclear medicine is a medical specialty that uses targeted drugs containing radioactive particles to image and treat disease. Nuclear medicine has a long history dating back to the early 1900s. Over the last 20 years, advances in this field brought new tools and techniques that help us see, treat and monitor disease inside our bodies, especially in cancer.

Two examples of these advances are Precision Radioligand Imaging and Targeted Radioligand Therapy.¹

Diagnostic Imaging

Precision Radioligand Imaging uses targeted drugs containing radioactive particles to see how the body is functioning and to observe its chemical and biological processes. Other diagnostic procedures, such as X-rays or computed tomography (CT) assist in detecting changes in the physical structures.²



Therapy

Nuclear medicine can be used as treatment for many diseases such as certain types of cancer. With Targeted Radioligand Therapy, a targeted drug containing a radioactive particle is injected into a patient's bloodstream and then it binds to a specific receptor expressed on a particular tumor cell. The radioisotope attached to the targeting molecule releases its radiation, damaging the tumor and nearby cells.^{1,3}

1. Advancing Nuclear Medicine Through Innovation: <https://www.ncbi.nlm.nih.gov/books/NBK11471/>

2. What are molecular imaging and nuclear medicine?: <https://www.snmmi.org/AboutSNMMI/Content.aspx?ItemNumber=6433>

3. About Targeted Radioisotope Therapies: [snmmi.org/Patients/About/content.aspx?ItemNumber=14792&navItemNumber=14793](https://www.snmmi.org/Patients/About/content.aspx?ItemNumber=14792&navItemNumber=14793)

Global Headquarters
Advanced Accelerator Applications SA
20 Rue Diesel - 01630 Saint-Genis-Pouilly - France
Tel: +33 (0)4 50 99 30 70 - Fax: +33 (0)4 50 99 30 71

US Headquarters
Advanced Accelerator Applications USA, Inc.
57 East Willow Street - Millburn, NJ 07041 - USA
Tel: +1-862-263-0820 - Fax: +1-832-263-0840

info@adacap.com
www.adacap.com

AAA-CORP-US-0050. September 2020